Posts Tagged ‘TRA’

January 13th, 2011

Merck’s Thrombin Receptor Antagonist Suffers Major Setback

Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is being discontinued and the trial will be closed out. The second trial, TRA-2P TIMI 50, is being curtailed but not stopped. The actions were based on recommendations from the combined Data and […]